These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

457 related articles for article (PubMed ID: 12823348)

  • 1. Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy.
    Lachmann HJ; Gallimore R; Gillmore JD; Carr-Smith HD; Bradwell AR; Pepys MB; Hawkins PN
    Br J Haematol; 2003 Jul; 122(1):78-84. PubMed ID: 12823348
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum levels of free light chain before and after chemotherapy in primary systemic AL amyloidosis.
    Matsuda M; Yamada T; Gono T; Shimojima Y; Ishii W; Fushimi T; Sakashita K; Koike K; Ikeda S
    Intern Med; 2005 May; 44(5):428-33. PubMed ID: 15942088
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantitative analysis of serum free light chains. A new marker for the diagnostic evaluation of primary systemic amyloidosis.
    Abraham RS; Katzmann JA; Clark RJ; Bradwell AR; Kyle RA; Gertz MA
    Am J Clin Pathol; 2003 Feb; 119(2):274-8. PubMed ID: 12579999
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of amyloidogenic light chains requires the combination of serum-free light chain assay with immunofixation of serum and urine.
    Palladini G; Russo P; Bosoni T; Verga L; Sarais G; Lavatelli F; Nuvolone M; Obici L; Casarini S; Donadei S; Albertini R; Righetti G; Marini M; Graziani MS; Melzi D'Eril GV; Moratti R; Merlini G
    Clin Chem; 2009 Mar; 55(3):499-504. PubMed ID: 19131635
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Amino acid sequence homology of monoclonal serum free light chain dimers and tissue deposited light chains in AL amyloidosis: a pilot study.
    Goldis R; Kaplan B; Arad M; Dispenzieri A; Dasari S; Kukuy OL; Simon AJ; Dori A; Shavit-Stein E; Ziv T; Murray D; Kourelis T; Gertz MA; Dominissini D; Magen H; Muchtar E
    Clin Chem Lab Med; 2024 Feb; 62(3):464-471. PubMed ID: 37747270
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Circulating free light chain measurement in the diagnosis, prognostic assessment and evaluation of response of AL amyloidosis: comparison of Freelite and N latex FLC assays.
    Palladini G; Jaccard A; Milani P; Lavergne D; Foli A; Bender S; Lavatelli F; Bosoni T; Valentini V; Pirolini L; Ferraro G; Basset M; Russo F; Nuvolone M; Albertini R; Cogne M; Merlini G
    Clin Chem Lab Med; 2017 Oct; 55(11):1734-1743. PubMed ID: 28343171
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Absolute values of immunoglobulin free light chains are prognostic in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation.
    Dispenzieri A; Lacy MQ; Katzmann JA; Rajkumar SV; Abraham RS; Hayman SR; Kumar SK; Clark R; Kyle RA; Litzow MR; Inwards DJ; Ansell SM; Micallef IM; Porrata LF; Elliott MA; Johnston PB; Greipp PR; Witzig TE; Zeldenrust SR; Russell SJ; Gastineau D; Gertz MA
    Blood; 2006 Apr; 107(8):3378-83. PubMed ID: 16397135
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum-free light-chain analysis in diagnosis and management of multiple myeloma and related conditions.
    Milani P; Palladini G; Merlini G
    Scand J Clin Lab Invest Suppl; 2016; 245():S113-8. PubMed ID: 27467897
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term follow-up of plasma cells in bone marrow and serum free light chains in primary systemic AL amyloidosis.
    Yoshida T; Matsuda M; Katoh N; Tazawa K; Shimojima Y; Gono T; Ishii W; Nakazawa Y; Sakashita K; Koike K; Yamada T; Ikeda S
    Intern Med; 2008; 47(20):1783-90. PubMed ID: 18854629
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Isolation and biochemical characterization of plasma monoclonal free light chains in amyloidosis and multiple myeloma: a pilot study of intact and truncated forms of light chains and their charge properties.
    Kaplan B; Ramirez-Alvarado M; Dispenzieri A; Zeldenrust SR; Leung N; Livneh A; Gallo G
    Clin Chem Lab Med; 2008; 46(3):335-41. PubMed ID: 18254719
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diagnostic and prognostic utility of the serum free light chain assay in patients with AL amyloidosis.
    Morris KL; Tate JR; Gill D; Kennedy G; Wellwood J; Marlton P; Bird R; Mills AK; Mollee P
    Intern Med J; 2007 Jul; 37(7):456-63. PubMed ID: 17547724
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Amyloid load and clinical outcome in AA amyloidosis in relation to circulating concentration of serum amyloid A protein.
    Gillmore JD; Lovat LB; Persey MR; Pepys MB; Hawkins PN
    Lancet; 2001 Jul; 358(9275):24-9. PubMed ID: 11454373
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quantitative serum free light chain assay in the diagnostic evaluation of AL amyloidosis.
    Akar H; Seldin DC; Magnani B; O'Hara C; Berk JL; Schoonmaker C; Cabral H; Dember LM; Sanchorawala V; Connors LH; Falk RH; Skinner M
    Amyloid; 2005 Dec; 12(4):210-5. PubMed ID: 16399645
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel approach for the purification and proteomic analysis of pathogenic immunoglobulin free light chains from serum.
    Lavatelli F; Brambilla F; Valentini V; Rognoni P; Casarini S; Di Silvestre D; Perfetti V; Palladini G; Sarais G; Mauri P; Merlini G
    Biochim Biophys Acta; 2011 Mar; 1814(3):409-19. PubMed ID: 21215335
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum-free light-chain assay: clinical utility and limitations.
    Bhole MV; Sadler R; Ramasamy K
    Ann Clin Biochem; 2014 Sep; 51(Pt 5):528-42. PubMed ID: 24489083
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [AL-amyloidosis and its treatment by eliminating the precursor protein].
    Verbeek DE; Hazenberg BP; Jager PL; Kremer Hovinga TK
    Ned Tijdschr Geneeskd; 2007 Sep; 151(37):2021-6. PubMed ID: 17929708
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum free light chain analysis may miss monoclonal light chains that urine immunofixation electrophoreses would detect.
    Shaheen SP; Levinson SS
    Clin Chim Acta; 2009 Aug; 406(1-2):162-6. PubMed ID: 19410572
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of the serum-free light chain test in untreated patients with AL amyloidosis.
    Bochtler T; Hegenbart U; Heiss C; Benner A; Cremer F; Volkmann M; Ludwig J; Perz JB; Ho AD; Goldschmidt H; Schonland SO
    Haematologica; 2008 Mar; 93(3):459-62. PubMed ID: 18287137
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Utility of the Serum Free Light Chain Assay in the Diagnosis of Light Chain Amyloidosis in Patients With Heart Failure.
    Chang IC; Dispenzieri A; Scott CG; Lin G; Jaffe AS; Klarich KW; Grogan M
    Mayo Clin Proc; 2019 Mar; 94(3):447-454. PubMed ID: 30718069
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changes in serum-free light chain rather than intact monoclonal immunoglobulin levels predicts outcome following therapy in primary amyloidosis.
    Kumar SK; Dispenzieri A; Lacy MQ; Hayman SR; Buadi FK; Zeldenrust SR; Tan T; Sinha S; Leung N; Kyle RA; Rajkumar SV; Gertz MA
    Am J Hematol; 2011 Mar; 86(3):251-5. PubMed ID: 21328431
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.